-
Presenter Profile: Next-Generation Pharmacotherapies to Reduce Hypoglycemia
Matthew J. Webber, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 1:30 p.m. CT.
-
Presenter Profile: Leveraging Artificial Intelligence for Precision Medicine in Youth-Onset Type 2 Diabetes
Mustafa Tosur, MD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 8:00 a.m. CT.
-
Presenter Profile: Understanding Diabetes Heterogeneity via Mining Multimodality Interconnected Data
Carl Yang, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 8:00 a.m. CT.
-
Authors of the Standards of Care in Diabetes—2026 will share insights on annual updates
This Saturday symposium, featuring Anne Peters, MD, Elizabeth Ann Beverly, PhD, Emily D. Szmuilowicz, MD, MS, and others, will cover chapters on diabetes technology, facilitating positive health behaviors, pharmacological approaches to glycemic management, cardiovascular disease and risk management, pregnancy, and diabetes in children and adolescents.
-
Experts to discuss AIDING results for automated insulin delivery in the hospital
Francisco Pasquel, MD, MPH, and other experts will share findings from this study evaluating automated insulin delivery initiated in the hospital compared with daily injections in people with type 1 or type 2 diabetes.
-
Trending topics in diabetes and obesity research and care highlight the 2026 Scientific Sessions program
Experts from across the globe will offer new perspectives on obesity, artificial intelligence, liver disease, behavioral health, women’s health, nutrition, new technology, and other trending topics in diabetes this June in New Orleans.
-
New clinical trial results to debut daily in New Orleans
Investigators will present high-impact results for type 1 diabetes, type 2 diabetes, and obesity in several clinical trial sessions. Glucagon-like peptide-1 (GLP-1)-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—will be a recurring topic.